We propose a three step framework for the evaluation of surrogate endpoints for health policy decisions on health technologies
In the drive toward faster patient access to treatments, health technology assessment (HTA) agencies...
Pivotal trials on morbidity and mortality (eg, in coronary heart disease, AIDS, cancer) are not only...
Background Opinions differ about the extent to which intervention research should and can directly a...
PublishedJournal ArticleThis is the author accepted manuscript. The final version is available from ...
The efficacy of medicines, medical devices, and other health technologies should be proved in trials...
The efficacy of medicines, medical devices, and other health technologies should be proved in trials...
The efficacy of medicines, medical devices, and other health technologies should be proved in trials...
Background. Surrogate endpoints (i.e., intermediate endpoints intended to predict for patient-center...
Background: Surrogate endpoints (i.e., intermediate endpoints intended to predict for patient-center...
In the drive towards faster patient access to treatments, health technology assessment (HTA) agencie...
In the drive towards faster patient access to treatments, health technology assessment (HTA) agencie...
Surrogate endpoints predict the occurrence and timing of a clinical endpoint of interest (CEI). Subs...
Decision uncertainty associated with reliance on surrogate endpoints is a risk to patients and socie...
In recent years, the cost of drug development has increased the demands on efficiency in the selecti...
The efficacy of health technologies, medicines and medical devices should be demonstrated in trails ...
In the drive toward faster patient access to treatments, health technology assessment (HTA) agencies...
Pivotal trials on morbidity and mortality (eg, in coronary heart disease, AIDS, cancer) are not only...
Background Opinions differ about the extent to which intervention research should and can directly a...
PublishedJournal ArticleThis is the author accepted manuscript. The final version is available from ...
The efficacy of medicines, medical devices, and other health technologies should be proved in trials...
The efficacy of medicines, medical devices, and other health technologies should be proved in trials...
The efficacy of medicines, medical devices, and other health technologies should be proved in trials...
Background. Surrogate endpoints (i.e., intermediate endpoints intended to predict for patient-center...
Background: Surrogate endpoints (i.e., intermediate endpoints intended to predict for patient-center...
In the drive towards faster patient access to treatments, health technology assessment (HTA) agencie...
In the drive towards faster patient access to treatments, health technology assessment (HTA) agencie...
Surrogate endpoints predict the occurrence and timing of a clinical endpoint of interest (CEI). Subs...
Decision uncertainty associated with reliance on surrogate endpoints is a risk to patients and socie...
In recent years, the cost of drug development has increased the demands on efficiency in the selecti...
The efficacy of health technologies, medicines and medical devices should be demonstrated in trails ...
In the drive toward faster patient access to treatments, health technology assessment (HTA) agencies...
Pivotal trials on morbidity and mortality (eg, in coronary heart disease, AIDS, cancer) are not only...
Background Opinions differ about the extent to which intervention research should and can directly a...
DOI
Add to ORKG